Compare EU & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | ANGO |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 530.2M |
| IPO Year | N/A | 2004 |
| Metric | EU | ANGO |
|---|---|---|
| Price | $2.64 | $12.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 2.9M | 381.2K |
| Earning Date | 11-10-2025 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $44,142,000.00 | ★ $300,718,000.00 |
| Revenue This Year | $17.41 | $8.18 |
| Revenue Next Year | $95.45 | $5.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $1.01 | $8.27 |
| 52 Week High | $4.19 | $13.99 |
| Indicator | EU | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 44.69 |
| Support Level | $2.35 | $12.76 |
| Resistance Level | $2.54 | $13.12 |
| Average True Range (ATR) | 0.18 | 0.38 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 64.60 | 8.21 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.